CytomX: Trading Near Cash Value While Varseta-M Heads Toward Pivotal Trials (NASDAQ:CTMX)
· seekingalpha.com
CytomX Therapeutics earns a Buy rating on strong Varseta-M colorectal cancer data, cash runway, and upside potential. Learn more about CTMX stock here.
I started my investing journey at age 18, and over the years, I have developed a disciplined strategy that has consistently outperformed the broader market. My ...